Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up

作者：Humam Kadara, M.-Y. Choi, J. Zhang, Edwin R. Parra, Jaime Rodriguez‐Canales, Stephen G. Gaffney, Zijin Zhao, C.F. Behrens, Jiro Fujimoto, Chi‐Wan Chow, Young-Bum Yoo, Neda Kalhor, César A. Moran, David L. Rimm, Stephen G. Swisher, Don L. Gibbons, John V. Heymach, Edward Kaftan, Jeffrey P. Townsend, Thomas J. Lynch, Joseph Schlessinger, J. Lee, Richard P. Lifton, Ignacio I. Wistuba, Ronald Herbst · 发表于：Annals of Oncology · 年份：2017 · DOI：10.1093/annonc/mdx062 · 被引用次数：33 · 研究领域：Cancer Genomics and Diagnostics、RNA modifications and cancer、Ferroptosis and cancer prognosis

Ann Oncol 2017; 28(1): 75–82 (doi:) This paper has been corrected to update two author affiliations. Y. Yoo’s affiliation was corrected from 3 to 9, and R. P. Lifton’s first affiliation was corrected from 2 to 3. Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-upAnnals of OncologyVol. 28Issue 1PreviewLung adenocarcinomas (LUADs) lead to the majority of deaths attributable to lung cancer. We performed whole-exome sequencing (WES) and immune profiling analyses of a unique set of clinically annotated early-stage LUADs to better understand the pathogenesis of this disease and identify clinically relevant molecular markers. Full-Text PDF Open Archive